Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

Insmed Headquarters

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

“While acknowledging that shares of Insmed are up over 450% (versus a 2% increase for the XBI) since the positive Phase III results with Brinsupri in bronchiectasis, we believe the potential for a strong commercial launch of Brinsupri in the multi-blockbuster bronchiectasis indication will keep Insmed as a ‘must-own’name for investors.”

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.